作者：Ralph Bocciaa, Imtiaz A. Malikb, Vinay Rajac, Stephen Kahanicd, Randall Liue,
Tom Lillief, Dianne Tomitaf, Billy Clowneyg, Peter Silbersteinh
【关键词】 Chemotherapy,•,Anemia,•,Darbepoetin,alfa,•,Hemoglobin,•,Cancer
ABSTRACT
Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 µg) Q3W in patients with CIA. Eligible patients (18 years) were anemic (hemoglobin <11g/dl), had a nonmyeloid malignancy, and were receiving multicycle chemotherapy. This analysis includes 1,493 patients who received at least one dose of darbepoetin alfa. The effect of baseline hemoglobin (<10 or 10 g/dl) on clinical outcomes was evaluated. Patients in the 10-g/dl stratum achieved the hemoglobin target range (1113g/dl)in less time than patients in the <10-g/dlstratum (3 weeks vs. 9 weeks). More patients in the 10-g/dl stratum achieved the h……
<<<<<全文未完，本文约118个中文字，未计算英文字母、数字>>>>>
